So the earlier parts of the trial we’ve compared patches to ADT in terms of quality of life and broadly the quality of life is slightly better on patches but with different pros and cons. So fatigue is less for example but gynaecomastia is worse. The sexual interest is better and hot flushes or flashes as you call them are also better. So we’ve done that piece of work...
So the earlier parts of the trial we’ve compared patches to ADT in terms of quality of life and broadly the quality of life is slightly better on patches but with different pros and cons. So fatigue is less for example but gynaecomastia is worse. The sexual interest is better and hot flushes or flashes as you call them are also better. So we’ve done that piece of work. We’ve done a separate piece of work on bone density so as with postmenopausal women you preserve bone density with oestrogen as opposed to losing it on ADT. It’s self-administered which means you don’t have to go to your family doctor to have an injection once every three months or whatever. The downside is you have to keep replacing the patches you’ve got either two or three patches on at a time you know they can produce skin reactions so that’s a potential downside but not a massive one for most of the men compliance was very good. So we think it’s an interesting new option. I mean it’s not a sexy new pharma drug, it’s a very old drug, but just because it’s old doesn’t necessarily mean it’s not an interesting new innovation in terms of how we’re using it. And as I said the cost savings are substantial. Now if you’re self-funding your medication that’s potentially very attractive.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
